AVIRHealthcare · BiotechnologyThe 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +81.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Atea Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (95): The share price has been relatively steady.
Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVIR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +81.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $6.00 → $7.00 |
| 9 Mar 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 9 Mar 2026 | Evercore ISI Group | Maintains | Outperform | $6.00 → $10 |
| 11 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Aug 2024 | Morgan Stanley | Upgrade | Equal-Weight | — |
| 10 Aug 2023 | JP Morgan | Downgrade | Underweight | — |
| 16 Mar 2023 | JP Morgan | Maintains | Neutral | — |
| 27 Jan 2023 | SVB Leerink | Maintains | Market Perform | — |
| 24 Jan 2023 | Morgan Stanley | Maintains | Underweight | — |
| 15 Aug 2022 | Morgan Stanley | Maintains | Underweight | — |
| 2 Mar 2022 | JP Morgan | Maintains | Neutral | — |
| 1 Mar 2022 | SVB Leerink | Maintains | Market Perform | — |
| 16 Feb 2022 | SVB Leerink | Maintains | Market Perform | — |
| 6 Jan 2022 | Morgan Stanley | Downgrade | Underweight | — |
| 18 Nov 2021 | SVB Leerink | Downgrade | Market Perform | — |
| 20 Oct 2021 | JP Morgan | Downgrade | Neutral | — |
| 20 Oct 2021 | SVB Leerink | Maintains | Outperform | — |
| 5 Oct 2021 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 9 Sept 2021 | SVB Leerink | Initiates | Outperform | — |
| 18 Aug 2021 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVIR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Atea Pharmaceuticals, Inc. returned +50.3% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 45% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atea Pharmaceuticals, Inc. has a market value of $435.5M and an enterprise value of $216.5M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$169.5M.
Diluted earnings per share, trailing twelve months: $−2.11.
Free cash flow in the twelve months to 31 Mar 2026: −$147.9M.
Atea Pharmaceuticals, Inc. spent $25.8M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: −2.8×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Atea Pharmaceuticals, Inc. employs 55 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Atea Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Atea Pharmaceuticals held its Q2 2026 earnings call, and the transcript of that call was published on Seeking Alpha. The item is limited to the availability of the earnings call transcript.
Why it matters — AVIR watchers would care because the earnings call transcript provides direct insight into the company's second-quarter 2026 financial results and management commentary.
Atea Pharmaceuticals reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C, with the study meeting primary and secondary endpoints compared to the standard-of-care regimen sofosbuvir/velpatasvir.
Why it matters — The positive Phase III results bring Atea's lead hepatitis C candidate closer to potential regulatory submission, representing a significant milestone for the company's pipeline.
Atea Pharmaceuticals announced its second quarter 2026 financial results and provided a business update. The company reported that its Phase 3 C-BEYOND trial of BEM/RZR met primary and secondary endpoints, including an 8-week treatment duration for HCV patients without cirrhosis.
Why it matters — The Phase 3 trial success with a short 8-week regimen could support a best-in-class profile for Atea's HCV treatment candidate BEM/RZR, a key pipeline catalyst for the company.
Atea Pharmaceuticals announced it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.
Why it matters — This item tells Atea investors when the company will report its second-quarter 2026 results and share a business update.
Atea Pharmaceuticals announced that its Bemnifosbuvir/Ruzasvir combination met both primary and secondary endpoints in the Phase 3 C-BEYOND North America trial for hepatitis C virus. The treatment achieved statistical non-inferiority compared to the standard-of-care Sofosbuvir/Velpatasvir in what the company described as the first successful head-to-head trial in a global Phase 3 HCV program.
Why it matters — The positive Phase 3 results advance Atea's lead HCV candidate toward a potential regulatory filing and position it as a competitive treatment option against an established standard-of-care.
The 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Atea Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atea Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Atea Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +81.8% from the last close, and Ticker Nerd's factor model ranks Atea Pharmaceuticals, Inc. 69 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Atea Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.
Atea Pharmaceuticals, Inc. returned +50.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript". Atea Pharmaceuticals held its Q2 2026 earnings call, and the transcript of that call was published on Seeking Alpha. The item is limited to the availability of the earnings call transcript.
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its variants. The company is also advancing bemnifosbuvir in combination with ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment, with this regimen currently in Phase 3 clinical trials. Additionally, Atea Pharmaceuticals develops AT-587 for chronic hepatitis E virus infection, which is in Phase 1 trials. Operating within the biotechnology sector of healthcare, the company holds a license agreement with MSD International GmbH for ruzasvir's development, manufacture, and commercialization. Founded in 2012 and headquartered in Boston, Massachusetts, Atea Pharmaceuticals plays a key role in advancing innovative oral therapies for viral diseases affecting global patient populations.
CEO Dr. Jean-Pierre Sommadossi Ph.D. · 55 employees · United States · https://ateapharma.com
